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AICARThe AMP-activated protein kinase agonist AICAR mimics a low intracellular energy state and inhibits the
proliferation of cancer cells by different mechanisms, which may depend on the bioenergetic signature of
these cells. AICAR can also stimulate mitochondrial biogenesis in myoblasts, neurons and HeLa cells. Yet,
whether the reactivation of oxidative phosphorylation biogenesis by AICAR contributes to the growth arrest of
cancer cells remains undetermined. To investigate this possibility, we looked at the impact of 24- and 48-hour
treatments with 750 μM AICAR on human cancer cell lines (HeLa, DU145, and HEPG2), non-cancer cells
(EM64, FM14, and HLF), embryonic cells (MRC5) and Rho0 cells. We determined the bioenergetic proﬁle of
these cells and assessed the effect of AICAR on oxidative phosphorylation biogenesis, cell viability and cell
proliferation, ROS generation, mitochondrial membrane potential and apoptosis induction. We also followed
possible changes in metabolic regulators such as Akt and Hif1-α stabilization which might participate to the
anti-proliferative effect of AICAR. Our results demonstrated a strong and cancer-speciﬁc anti-growth effect of
AICAR that may be explained by three different modes according to cell type: the ﬁrst mode included
stimulation of the mitochondrial apoptotic pathway however with compensatory activation of Akt and
upregulation of oxidative phosphorylation. In the second mode of action of AICAR Akt phosphorylation was
reduced. In the third mode of action, apoptosis was activated by different pathways. The sensitivity to AICAR
was higher in cells with a low steady-state ATP content and a high proliferation rate. This article is part of a
Special Issue entitled: Bioenergetics of Cancer., 5-amino-4-imidazolecarbox-
ator; ATP, adenosine triphos-
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The bioenergetic proﬁle of a given tumor can vary widely from
glycolytic to oxidative, according to the oncogenes activated and the
microenvironment [1–5]. The typical “glycolytic” type of cancer cells
presents an enhanced glycolytic machinery confronted to a less
efﬁcient OXPHOS system, while the “OXPHOS” type of cancer cells
relies mainly on mitochondrial respiration to produce ATP from
glucose and glutamine oxidation [6–8]. It was demonstrated that
mitochondrial oxidative phosphorylation is of low efﬁciency inglycolytic tumors, notably through a reduction of mitochondrial
content [9–13]. Therapeutic strategies able to interfere speciﬁcally
with the pathways primarily used by cancer cells for energy
production could ideally permit to reduce tumor growth [14,15]. As
each cancer cell type presents their own bioenergetic signature
[5,16–18], pharmacological attempts to interfere with distinctive
steps of cancer energy production pathways could provide drug
speciﬁcity. Hence, a potential therapeutic strategy may begin with the
determination of the bioenergetic signature of tumors [7,10,19–22]
followed by the reactivation of the mitochondrial oxidative metab-
olism in glycolytic tumors with ineffective mitochondria, when
appropriate. Indeed, stimulation of PDH activity with sodium-
dichloroacetate [23] or overexpression of frataxin [24] reduced the
proliferation of colorectal cancer cell lines and colon cancer cells,
respectively. Another possibility could consist in the global stimula-
tion of mitochondrial biogenesis in cancer cells with a reduced
mitochondrial content and OXPHOS capacity. In a previous study
performed on lung epidermoid carcinoma cells we attempted to
reactivate mitochondrial biogenesis by using resveratrol [10], a
polyphenol that activates Sirt1 and promotes PGC1-α deacetylation,
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trol, we observed a rapid and speciﬁc loss of cancer cell viability, while
non-cancer lung ﬁbroblasts treated with the same doses presented a
stimulation of mitochondrial energy metabolism and increased cell
viability [25]. In the present article, we followed on this strategy by
using the AMP-activated protein kinase agonist AICAR, which was
shown to stimulatemitochondrial biogenesis in skeletal muscle [26,27]
and cultured cells as diverse as neurons [28], myocytes [29] and
myotubes [26]. In addition, a potent anti-tumoral effect was demon-
strated for AICAR in pancreatic cancer cells [30], melanomas [31],
cervical cancer [32–34], breast cancer cells [35,36], leukemia-derived
lymphoblasts [37], glioblastomas [38], prostate cancer cells [36,39,40],
hepatomas [41], myelomas [42], colon and gastric cancer cells [43–45],
hematological cell lines [36], C6 gliomas [36], astrocytomas [36,46] and
chronic myelogenous leukemia cells [36]. Furthermore, when admin-
istered in vivo, AICAR attenuated the growth of MDA-MB-231 tumors
and of glioblastomaxenografts in nudemice [38,47]. However, eventual
changes in mitochondrial or OXPHOS content by AICAR were not
investigated as one participating mechanism to the observed anti-
proliferative effects of this drug on cancer. In addition to possible
changes in OXPHOS biogenesis, AICAR could also modulate cancer cell
proliferation by acting on Akt phosphorylation and HIF1α content, both
of which are potent regulators of cancer cell proliferation and
energetics. Lastly, the reduction of cancer cell viability induced by
AICAR might also include the activation of apoptosis, and this
mechanism remains to be evaluated.
Here, we analysed the impact of 24- and 48-hour treatments with
750 μMAICAR on the viability of cancer and non-cancer cells. We used
tumor-derived cell lines with native differences in their bioenergetic
proﬁle as well as Rho0 cells to evaluate the link between the cellular
energy state and the sensitivity to AICAR. To investigate the cell-type
speciﬁc impact of AICAR in the cell lines tested, we determined
changes in OXPHOS content, induction of apoptosis, generation of ROS
and activation of the Akt–GS3K survival pathway.
2. Materials and methods
2.1. Chemicals
All the reagents including AICAR (Aminoimidazole-4-carboxamide-
1-β-D-ribofuranosyl 5′-monophosphate) were purchased from Sigma-
Aldrich, with the exception of the ATP monitoring kit (ATP Biolumi-
nescence Assay Kit HS II from Roche).
2.2. Cell types and culture conditions
HeLa, DU145, HEPG2, HLF and MRC-5 cells were purchased from
the American Type Culture Collection (ATCC). The primary monolayer
epithelial cell line EM64 and the primary monolayer ﬁbroblasts FM14Table 1
Cell lines description and bioenergetic proﬁle.
Cell line Organ Cancer-type Morphology Age
Cancer cell lines
HeLa Cervix Adenocarcinoma Epithelial 31
DU145 Prostate Carcinoma Epithelial 69
HEPG2 Liver Hepatocellular carcinoma Epithelial 15
Non cancer cell lines
EM64 n.d. Normal Epithelial Adult
FM14 Skin Normal Fibroblast Adult
HLF Lung Normal from tissue surrounding
epidermoid carcinoma
Fibroblast-like 54
Rho 0 Skin BET treated Epithelial Adult
MRC-5 Lung Embryonic Fibroblast Fetal (14-week
(n.d.: not determined).were prepared in our laboratory. The primary ﬁbroblasts derived Rho0
cells were prepared by using 2′3′-dideoxycytidine as we detailed in
[48]. A description of each cell line is given in Table 1. Cells were
grown in Glucose Dulbecco's Modiﬁed Eagle Media (DMEM) contain-
ing 25 mM glucose supplemented with 10% fetal bovine serum (PAA),
100 U/ml penicillin, and 100 U/ml of streptomycin. All cells were kept
in 5% CO2 at 37 °C. For all experiments cells were harvested during
exponential phase of growth at 70% conﬂuency.
2.3. Cell enumeration and cell viability
The cytotoxicity of AICAR was evaluated on the different cell lines
by counting the cells after 48 h of treatment with 750 μMAICAR using
a Malassez haemocytometer. Cells were seeded in 6 well plates
(100 000 cells per well) and treated with 750 μM AICAR for 48 h.
Then, cells were trypsinized and counted manually (NN3 for each
condition). Cell viability was measured using the neutral red assay as
detailed by Borenfreund [49,50]. Absorbance was measured in a
multi-well scanning spectrophotometer (MP96 from SAFAS) at a
wavelength of 540 nm with a reference set at 630 nm. For each
condition, multiple replicates (nN6) were performed. The results
were expressed as percent value of the control absorbance ratio.
2.4. ATP measurements
The intracellular ATP content was measured by using the
bioluminescent ATP kit HS II (Roche Applied). Cells treated or not
with AICAR were washed with PBS, detached with trypsin and
resuspended in DMEM (100 μl of a cell suspension of 2×106cells/ml).
For each cell type one aliquot was used to measure the total ATP
content, while the second aliquot was treated with antimycin A for
20 min to block mitochondrial ATP synthesis and allow ATP turnover
by the ATP consuming processes. In a third aliquot, glycolysis was
blocked with 200 μM iodoacetate to evaluate the participation of
glycolysis to cellular ATP synthesis. Then, cells were lysed to release
the intracellular ATP by using the lysis buffer provided with the kit
(equal volume) for 20 min. 100 μl of this lysate was analysed in a 96
well plate luminometer (Luminoskan) using the luciferine–luciferase
reaction system provided with the kit. 100 μl of luciferine/ase was
injected in thewells and after 10 s of incubation, bioluminescencewas
read (1 s integration time). Standardization was performed with
known quantities of standard ATP provided with the kit measured in
the same conditions. The contribution of glycolysis and oxidative
phosphorylation to cellular ATP synthesis was obtained by calculating
the ratio of the ATP content in cells treated with antimycin (glycolytic
ATP remains) to that determined in untreated cells (glycloysis+
OXPHOS). The amount of ATP produced by OXPHOS was veriﬁed in
cells treated with iodoacetate (glycolysis is blocked) and similar
results were obtained.Gender Ethnicity Tumorigenic Total ATP
(pmoles per 1.10E5 cells)
% Glycolytic
ATP
Female Black n.d. 0.53 79
Male Caucasian Yes 0.63 96
Male Caucasian Yes 0.61 76
n.d. n.d. No 0.96 71
Female Caucasian No 1.40 48
Female Black No 1.52 54
Female Caucasian No 0.71 100
old) Male Caucasian No 0.63 95
Fig. 1. Growth properties and energy metabolism of cancer cells and non-cancer cells. (A) Correlation between the percentage of mitochondrial ATP production and the total cellular
ATP content in the different cell lines. (B) Cell proliferation rate of the different cell lines measured over 48 h; cell culture was initiated with 10 000 cells. (C) Cell growth rate was
plotted as a function of the cellular steady-state ATP content. All the data shown correspond to the mean value±SD of N≥3 different experiments.
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Fig. 2. Impact of a 48 h treatment with 750 μM AICAR on cell viability. The neutral red assay was performed on the different types of cells and the IC50 was determined by a ﬁtting
procedure (Excel) using a four parameter model. All the data shown correspond to the mean value±SD of N≥3 different experiments. N.A. = Not Applicable (the data cannot be
ﬁtted as no inhibition is observed) in the non-cancer cells.
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and ROS cytosolic concentration on cell populations
Cells were trypsinized, counted, and incubated in the presence of
750 μM AICAR for 24 h in DMEM. TMRM (Invitrogen) was used for
measuring the relative mitochondrial membrane potential. Changes
in cytosolic ROS levels were monitored using the CM-H2DCFDA
probe. These probes were added in the cell suspension in the
presence of AICAR, and incubated for 30 min at 37 °C, according to
the manufacturer's protocol. Cells were washed in PBS, and
ﬂuorescence was measured in a quartz cuvette on a Xenius
spectroﬂuorometer (SAFAS). A second reading was performed with
the addition of 100 μM H2O2 in the cuvette to verify the response
and the absence of saturation of CM-H2DCFDA probe. The signal
increased immediately after the addition in a dose dependent
manner. In the same manner, a second reading was performed with
the addition of 100 μM FCCP for the TMRM probe (results not
shown) and the signal decreased immediately. The ﬂuorescence
value measured after FCCP was close to zero and similar in all the
samples tested. We expressed the ΔΨ as the difference between
TMRM ﬂuorescence measured in the sample and that measured after
FCCP addition.2.6. Assessment of mitochondrial network morphology, and single cell
evaluation of ROS level and ΔΨ by ﬂuorescence microscopy
Cells were grown in 6 well plates for 24 h in the presence or not of
750 μM AICAR. The mitochondrial network was stained with the
Mitotracker green dye (Invitrogen), used at 60 nM for 15 min at 37 °C.
Cytosolic ROS were detected with CM-H2DCFDA (Invitrogen) used at
5 μM for 30 min as detailed in [51] and relative ΔΨ was evaluated
with TMRM used at 60 nM for 30 min, as described in [51]. The probes
were added directly to the wells under the continuous presence of
AICAR. For these observations we used a Nikon E 200 microscope,
with a 60×, 1.4 N.A water immersion objective. A series of images was
acquired using a Q-Imaging Retiga Exi fast 1394 digital camera, driven
by Fluo'up (Explora Nova, France). Image analysis was performed
with Morpho pro v2.8 (Explora Nova, France).
2.7. Western-blotting
Total cell lysis was performed using 0.4% lauryl-maltoside, for
30 min on ice. Samples were diluted into a SDS-PAGE tricine sample
buffer (Bio-Rad) containing 2% β-mercaptoethanol by incubation for
30 min at 37 °C, and separated on a 4–20% SDS polyacrylamide
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were transferred electrophoretically to 0.45 μm polyvinylidine
diﬂuoride (PVDF) membranes for 2 h at 100 mA in CAPS buffer
(3.3 g CAPS, 1.5 l 10% methanol, pH 11) on ice. Membranes were
blocked overnight in 5%milk-PBS+0.02% azide, and incubated for 4 h
with the primary antibodies. Polyclonal antibodies against caspase 3,
PARP, phospho-Akt-Ser473 and phospho-GS3Kβ and monoclonal
antibodies against Hif1α, β-actin, MnSOD were obtained from Santa
Cruz Biotechnology. Monoclonal antibodies against respiratory chain
complexes were obtained fromMitosciences (OXPHOS cocktail). After
six washes with PBS−0.05% Tween 20, the membranes were
incubated for 1 h with horseradish peroxidase-conjugated goat anti-
rabbit (Bio-Rad), or bovine anti-goat diluted in 5% milk-PBS. This
secondary antibody was detected in a Chemidoc (biorad) using the
chemiluminescent ECL PlusTM reagent (Amersham). The signal was
quantiﬁed by densitometric analysis using Image J (NIH) software.
2.8. Statistical analysis
All the data presented in this study correspond to the mean value
of N experiments±SD, with N≥3. Comparison of the data sets
(control versus AICAR treated) was performed with the Student's
t test, using Excel Software (Microsoft). Two sets of data were
considered statistically different when Pb0.05.
3. Results
3.1. Metabolic proﬁle of the tumor-derived cell lines and of the primary
cells
We measured the relative contribution of glycolysis and of
oxidative phosphorylation (OXPHOS) to the cellular ATP production
(Table 1). This was obtained by using speciﬁc inhibitors of glycolysis
(iodoacetate) and of OXPHOS (antimycin). In Table 1, the tissue of
origin and the type of tumor from which the cancer cell lines
originated are speciﬁed. It can be seen that all the tumor-derived cell
lines used in this study produced their vital ATP mainly through
glycolysis (from 76 to 96% of the total ATP produced), while non-
cancer cells relied on glycolysis to a lesser extent (from 48 to 71%). As
expected, the Rho0 cells, depleted of mitochondrial DNA, relied
exclusively on glycolysis to produce ATP. The embryonic lung
ﬁbroblasts (MRC-5) also used glycolysis to a large extent (95%). TheFig. 3. Effect of AICAR on cell number (after 48 hours of growth.). The results are expres
All the data shown correspond to the mean value±SD of N≥3 different experiments. p
untreated ones.total ATP content was higher in non-cancer cells (HLF, EM64 and
FM14) as compared to cancer cells, which positively correlated
(R2=0.71, p=0.0148) with the degree of OXPHOS utilization for ATP
synthesis (Fig. 1A). The rate of cell proliferation was evaluated by
measuring the net increase in cell number after 48 h of growth
(Fig. 1B). HeLa and DU145 were fast-growing cancer cell lines in
contrast with HEPG2. The non-cancer cells (FM14, EM64 and HLF)
showed a lower rate of cell proliferation (mean value of 50% increase
in cell number after 48 h) as compared to the cancer group (294%).
The embryonic cell line MRC-5 presented a rather high proliferation
rate (208%) intermediate between the cancer cells and the control
cells, as was the case of Rho0 (106%). Lastly, cells with a high
proliferation rate showed low steady-state values of total ATP content,
and reciprocally (Fig. 1C).
3.2. AICAR treatment decreases proliferation and viability of cancer cells
We treated the different cell-lines with increasing concentrations
of AICAR (from 50 μM to 1 mM) for 48 h and measured cell viability
using the neutral red assay (Fig. 2A–H). AICAR was present during all
the measurements described below (continuous AICAR treatment).
The calculated IC50 values for AICAR are given in Fig. 2. In striking
contrast with the non-cancer cells and the Rho0 cells, we observed a
clear dose-dependent inhibition of neutral red uptake in all the cancer
cells tested (IC50 values ranging from 99 to 500 μM) and in the
embryonic cell line (IC50=750 μM), suggesting a decrease in viability
upon treatment of cancer cells with AICAR. As the neutral red uptake
test depends both on cell number and cell metabolic activity, we
assessed the actual decrease in cell number induced by AICAR (Fig. 3).
We observed no increase in the number of dead cells in the culture
dishes at 12, 24 and 48 h (data not shown). Instead, AICAR treatment
strongly reduced the proliferation of cancer cells (HeLa, DU145 and
HEPG2) after 48 h of treatment (55, 95 and 85% of inhibition
respectively), while no signiﬁcant or little effect was observed for
the non-cancer epithelial cells EM64, skin ﬁbroblasts FM14 and HLF
(16, 1 and 7% of inhibition respectively). The embryonic non-cancer
cell line MRC-5 showed a strong decrease in cell number (55% of
inhibition). A comparison of the effect of AICAR on cell number and
cell viability (Fig. 3) indicated a stronger effect of AICAR on the latter.
For instance, the prostate cancer cell line DU145 showed a reduction
by 70±06% of the cell number, while viability was reduced by
95±03%.sed as percentage of cell viability or cell number obtained in the untreated controls.
values were obtained from the comparison of the AICAR treated samples with the
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We evaluated the degree of apoptosis induction by measuring the
increase in caspase 3 and PARP protein content (active forms) after
treatment of the cell lines with 750 μMAICAR for 24 h (Fig. 4A and B).
Although the inactive (uncleaved) form of PARP was observed in all
the cell lines at the exception of FM14 and HEPG2, its active form was
only detected in HLF cells under normal conditions. In HLF, AICAR
treatment induced an increase (363%, pb0.05) in the active form of
PARP, as well as that of caspase 3 (825% of the untreated control,
pb0.05). Interestingly, Akt phosphorylation at serine 473 was
increased in HeLa, MRC-5 and HLF (140, 126 and 163% of the
untreated control, respectively). In contrast, Akt phosphorylation
(activation) was signiﬁcantly reduced in DU145 and HEPG2. We also
looked at the overall morphology of the mitochondrial network
(Fig. 5) which typically harbors a fragmented shape when apoptosis is
induced [52]. In accordance with the levels of PARP and caspase-3, no
sign of fragmentation of the mitochondrial network was noticed at
4 h, 8 h, 12 h 24 h and 48 h in the cell-lines following the treatment
with AICAR (in this ﬁgure the 24 h data are shown). The Rho0 cells
show a fragmented mitochondrial network in the control conditions,
and no further fragmentation was observed after the AICAR
treatment.Fig. 4. Effect of AICAR on apoptosis and cell survival. (A) Western blot analyses performed
expression levels (normalized to actin) of signaling and apoptosis proteins in cell treated wit
different experiments. p values were obtained from the comparison of the AICAR treated sa3.4. Impact of AICAR treatment on the cell cycle regulator GSK3β
Glycogen synthase kinase-3beta (GSK3β) generally represses cell
cycle progression by direct phosphorylation of cyclin D1 [53]. As
AICAR treatment inhibited the proliferation in cancer cells, we
measured possible changes in the phosphorylation status of GSK3β
by western-blot (Fig. 4A and C). We observed a signiﬁcant increase in
GSK3β phosphorylation in EM64, DU145 and HeLa cells (286, 167 and
131% of the untreated control, respectively). In contrast, GS3Kβ
phosphorylation was reduced in Rho0, HEPG2 and HLF cells (64, 32
and 53% of the untreated control, respectively).
3.5. Modulation of OXPHOS content by AICAR
The expression level of ﬁve mitochondrial respiratory chain
proteins was evaluated by western blot and the individual modiﬁca-
tions (mean±SD values and p values) are given in (Fig. 6A and B). In
MRC-5 and HeLa cells treated with 750 μM AICAR there was a
signiﬁcant increase (pb0.05) in the levels of (+22% mean value).
Conversely, in EM64, DU145 and Rho0 cells, there was a signiﬁcant
reduction (−22% mean value, Pb0.05). We also tested the impact of
the AICAR treatment on Hif1α as this transcription factor plays a
central role in the metabolic remodeling of cancer cells. Hif1α wason 20 μg of proteins taken from cell treated with 750 μM AICAR for 48 h. (B) Protein
h 750 μMAICAR for 24 h. All the data shown correspond to the mean value±SD of N≥3
mples with the untreated ones.
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triggered a signiﬁcant increase (Pb0.05) of its content (+56%) solely
in the embryonic MRC-5 ﬁbroblasts.Fig. 5. Impact of AICAR on the fragmentation of the mitochondrial network. The
mitochondrial network was stained with Mitotracker Green in cells treated (right
panel) or not (left panel) for 24 h with 750 μM AICAR. No sign of mitochondrial
fragmentation was observed in all the cells except for the Rho0 cells where the
untreated controls exhibited a fragmented mitochondrial network.3.6. Effect of AICAR on oxidative stress and antioxidant defenses
To evaluate changes in oxidative stress possibly mediated by the
AICAR treatment we monitored intracellular DCFDA-detectable
oxidants production by measuring CM-H2DCFDA ﬂuorescence
(Fig. 7A). A signiﬁcant reduction (Pb0.05) of CM-H2DCFDA ﬂuores-
cence was noticed in HeLa cells (−50%), FM14 cells (−66%) and
MRC-5 cells (−29%). This was correlated with a signiﬁcant increase in
the expression level of MnSOD (Fig. 4A and B) in HeLa cells (+ 39%)
and MRC5 cells (+20%). Conversely, in HEPG2, EM64, HLF and Rho0
cells the AICAR treatment induced a signiﬁcant increase in ROS levels
(ranging from 29% in HEPG2 to 51% in HLF). Fluorescence microscopy
analyses (Fig. 7B) revealed the presence of ROS in the cytosol and the
mitochondrion, as conﬁrmedwith the co-staining of DU 145 cells with
CM-H2DCFDA and TMRM (Fig. 7B lower panel).
3.7. Effect of AICAR on mitochondrial membrane potential (ΔΨ)
Moderate changes in mitochondrial ΔΨ reﬂect variations in
respiratory chain activity, while a large drop in ΔΨ can indicate the
onset of apoptosis. Here, we monitored the relative changes in ΔΨ
after 24 h of treatment with 750 μM AICAR by measuring TMRM
ﬂuorescence (Fig. 8). The results showed a signiﬁcant decrease of ΔΨ
in DU145 (−16%), HEPG2 (8%), EM64 (−25%) and FM14 (−14%).
Conversely, TMRM ﬂuorescence was increased in HeLa cells (+27%),
HLF cells (+16%) and Rho0 cells (+12%). We veriﬁed that in our
experimental conditions TMRM entered the mitochondrion and did
not show unspeciﬁc staining (data not shown).
4. Discussion
The main ﬁndings of our study are the strong inhibition of cancer
cell's viability and proliferation by AICAR without affecting non-
cancer cell's viability and proliferation. Numerous studies have
reported the anti-proliferative effect of AICAR on cancer cells but
often lacked a comparison with paired non-cancer cells, and therefore
data about cancer-speciﬁcity of AICARmust be used with caution. Our
data indicate a strong effect of AICAR on the cancer prostate
carcinoma cell line DU145 and the hepatocellular carcinoma HEPG2
cell line (IC50 of 100 μM). The epidermoid carcinoma HeLa cells were
less sensitive to this treatment (IC50 of 500 μM) as was the embryonic
cell line MRC-5 (IC50 of 750 μM). All these cells share in common a
high contribution of glycolysis to the cellular ATP production (ranging
from 76% in HEPG2 to 96% in DU145) and a low steady-state ATP
content, as compared to the non-cancer cells used in our study and
that were not affected by AICAR. This suggests that cells with low
steady-state ATP content are more sensitive to AICAR. Cells with the
highest sensitivity to AICAR were also those in which (i) the
contribution of OXPHOS to ATP synthesis was low, and (ii) cell
proliferation rate was rapid, suggesting that cancer cells of the
glycolytic type could be preferentially targeted by treatment with
AICAR-type compounds. Not surprisingly, the growth of the embry-
onic cell line MRC-5 was also inhibited by AICAR as previous studies
have reported similarities between embryonic cells and cancer cells,
with regard to the regulation of energy metabolism. Accordingly, it
would be expected that a high mitochondrial bioenergetic activity
would protect against the anti-proliferative effect of AICAR [54]. In our
study, we observed that cancer cells present a higher proliferation
rate as compared to the non-cancer cells. Yet, differences in the tissue
of origin and the type of oncogene activated as well as disparities in
the preferential energy substrate could explain differences in the
observed proliferation rates.
No sign of cell death was observed in the cancer group during the
AICAR treatment, as well as no induction of apoptosis, as veriﬁed by
the absence of caspase 3 and PARP activation or the lack of
mitochondrial network fragmentation and deep decrease in ΔΨ at
Fig. 6. Effect of AICAR on OXPHOS biogenesis. (A) Western blot analyses performed on 20 μg of proteins taken from cell treated with 750 μM AICAR for 48 h. (B) Densitometric
analyses of the expression level of ﬁve mitochondrial respiratory chain proteins normalized to the actin levels. All the data shown correspond to the mean value±SD of N≥3
different experiments. The p values (Student t test) are given for each bar. p values were obtained from the comparison of the AICAR treated samples with the untreated ones.
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after the 48 h treatment with 750 μM AICAR can be attributed to a
lowered rate of cell proliferation, as previously reported on different
cancer cell lines [30,33,37].
The main question we intended to address in our study was the
impact of the AICAR treatment on mitochondrial biogenesis in cancer
cells and non-cancer cells. To do so we measured the changes in the
expression level of ﬁve mitochondrial respiratory chain proteins after
treatment with AICAR. The effects of AICAR on OXPHOS content were
cell-type speciﬁc. We found an increase in OXPHOS components in
HeLa,MRC-5 (around 30 to 50% increase) andHLF cells (20% increase),
while a reduced level of these proteins was observed in EM64, FM14,
DU145 and Rho0 cells (around −20%). Therefore, our observations
indicate that the preferential anti-proliferative effect of AICAR on
cancer cells did not include a consistent stimulation of OXPHOS
biogenesis, in contrast with our hypothesis. Likewise, the observed
increase in ROS levels in EM64 and HLF cells was not associated with
the sensitivity to AICAR, in comparisonwith other cell lines tested [55].
However, we did observe an antioxidant effect in HeLa and MRC-5
cells. The activation of Akt by AICAR followed a similar cell-type
speciﬁc pattern, as Akt phosphorylation was increased in HeLa cells
(+50%), MRC5 cells and HLF cells, but it was reduced in DU145 and
HEPG2. Sengupta et al. [37] proposed that Akt activation induced by
AICARmay represent a compensatory survivalmechanism in response
to apoptosis and/or cell cycle arrest triggered by this drug. Our
observations also suggest that cancer cell elimination might be
obtained by using AICAR in combination with Akt inhibitors.
Overall, our study evidenced clear differences in the effect of AICAR
on apoptosis induction, mitochondrial biogenesis stimulation, ROS
generation and Akt activation, which clearly indicate a cell-typespeciﬁc response to the AICAR treatment. As deduced from different
studies and from our data, three mechanisms could explain the anti-
cancer properties of AICAR (Table 2). The ﬁrst mechanism includes
cell cycle arrest and stimulation of the mitochondrial apoptotic
pathway with compensatory activation of Akt and stimulation of
OXPHOS biogenesis. This mechanism was recently described in
leukemia cells [37] and HeLa cells [33]. The second mode of action
of AICAR also includes cell proliferation arrest, but Akt phosphoryla-
tion is reduced instead of being activated. Consequently, this second
mechanism can be observed in cancer cells where Akt was primarily
activated, and for which glycolysis is also typically up-regulated [56].
In the third mode of action of AICAR, cancer cells die from apoptosis,
as mediated by different pathways (Table 2). Yet, although previous
studies indicated the possible activation of apoptosis by AICAR, our
results evidenced no signiﬁcant changes in caspase 3 cleavage upon
AICAR treatment. The apparent discrepancy observed between our
results and the studies listed in Table 2, with regard to the possible
activation of apoptosis by AICAR, might be explained by differences in
the type of cancer cells investigated which may present variable
dysregulation of the apoptotic pathways.
In our study, the impact of AICAR on DU145 and HEPG2 cells
presented similaritieswith the secondmechanism, as cell proliferation
was reduced and a reduction of Akt was also observed. HeLa cells
followed the ﬁrst mode of action of AICAR since Akt was activated by
AICAR, and induction of apoptosis was not observed. Lastly, HLF cells
showed an increased apoptosis with an increased activation of Akt,
which resembles the third mechanism. HLF cells are lung non-cancer,
as are MRC5, and both demonstrated changes in cell proliferation and
Akt after the AICAR treatment, which suggests that AICAR does not
target speciﬁcally cancer cells. Indeed, the state of Akt activation, cell
Fig. 7. Effect of AICAR on oxidative stress. (A) Intracellular ROS levels were determined using the ﬂuorescent probe CM-H2DCFDA on 0.5×1E5 cells/ml after 24 h of treatment with
750 μMAICAR. * P≤0.05. (B) CM-H2DCFDAmeasurement by ﬂuorescence microscopy in single cells after 24 h of treatment with 750 μMAICAR. All the data shown correspond to the
mean value±SD of N≥3 different experiments.
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sensitivity to AICAR, rather than the sole cancer origin of the cell
exposed to this drug. This might explain the important undesired
effect of this drug in clinical trials [57].
The changes in mitochondrial respiratory chain content following
AICAR treatment revealed cell speciﬁc responses with large variations.
First, we observed an increased content of OXPHOS proteins in cancer
(HeLa) and non-cancer cells (MRC5 and HLF) where AICAR also
activated Akt and triggered a stimulation of MnSOD expression. A
previous study performed on endothelial cells also showed that AICAR
stimulates both the expression of MnSOD and increases OXPHOS
content through the activation of the AMPK-PGC1α pathway [55]. In
HeLa, MRC-5 and HLF all the respiratory chain proteins analysed
showed an increased expression, while in HEPG2 the increase was
only observed for complex I and complex IV. However, the reduction
of respiratory chain content observed in DU145, Rho0 and EM64
suggests the inhibition of OXPHOS or the activation of mitophagy.Therefore, AICAR can trigger two opposite responses in different cell
lines, but their determinants remain unclear. We think that the
bioenergetic proﬁle of the cell and its capacity to adapt the energy
producing machinery to a low energy-state vary widely between
different cell types, explaining the differences of AICAR effects which
mimic such a low energy-state. For instance, we observed recently
that breast cancer cells reduce their mitochondrial content in hypoxic
conditions, while the corresponding non-cancer cells present an
opposite increased mitochondrial content [22]. In particular, our
study of the impact of AICAR on different cell types evidenced a
stronger anti-growth effect on cells withmore active proliferation and
a low steady-state ATP content, which might reﬂect an active
anabolism and a strong energy need, with a corresponding capacity
for bioenergetic adaptation. Interestingly, the Rho0 cells which solely
rely on glycolysis to survive were not affected by the AICAR treatment,
indicating that the pathway primarily used for energy production
does not determine by itself the sensitivity to AICAR. The
Fig. 8. Effect of AICAR on mitochondrial membrane potential. Mitochondrial membrane potential was determined using the ﬂuorescent probe TMRM on 0.5×1E5 cells/ml after 24 h
of treatment with 750 μM AICAR. * P≤0.05. All the data shown correspond to the mean value±SD of N≥3 different experiments.
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effects according to the type of cells investigated. Instead, as discussed
above, the energy status of the cell might determine the impact of
AICAR on a given cell line. Likewise, cancer cells and non-cancer cells
adapt differently to an increase in energy demand induced by glucose
deprivation or oxygen low availability, as occurs in solid tumors
[21,22].
5. Conclusions
Our data show that AICAR inhibits the growth of cancer cells in a
cell line speciﬁc manner. The activation of OXPHOS biogenesis by
AICAR is not a consistent property of this drug as the mitochondrial
content was even reduced in three cell lines treated with AICAR. The
diversity of mechanisms by which AICAR inhibits cancer cellTable 2
Cell-type dependent modes of action of AICAR.
Apoptosis Akt activation Mt-biogenesis ROS Cell death Cell proliferati
↑ ↑ n.d. ↑↓ ↓ p27 p53 (up)
↑ n.d. ↓
– ↑ ↑ ↓ ↓
– ↑ ↑ – ↓
↓ n.d. ↓
↑ p53 ↓ n.d. ↑ ↓ mTOR (down
↓ n.d. ↓ p21, 27, 53 (
↓ n.d. ↓ ERK–S6K–mT
– ↓ ↓ ↑ ↓
– ↓ ↓ ↑ ↓
n.d. ↓
n.d. ↓
n.d. p21 (up)–lipog
Glycolysis ↓ ↓ lipogenesis d
↑ n.d. ↑
↑ NF-kappaB n.d. ↑ ↑
↑ Trail n.d. ↑
↑ n.d.
↑ p53–p38–cjun n.d.
↑ n.d.
↑ n.d.
↑ n.d.
(n.d.: not determined).proliferation allows distinguishing three modes of action which may
depend on cell line speciﬁc energy status and bioenergetic proﬁle. Our
study complements that byMukherjee and colleagues [41] reinforcing
the conclusion that cancer cells and non-cancer cells are differentially
affected by AICAR, and our results further indicate that AICAR
increases OXPHOS content in a subset of cancer cells. In clinical trials,
AICAR has proven highly toxic [57] and produces undesired metabolic
effects that limit its utilization in cancer therapies. Yet, the strategy of
mimicking a low-energy state in cancer cells to trigger cell
proliferation arrest and apoptosis is still valid, and the research for
identifying novel energy restriction-mimetic agents (ERMAs) [58]
capable of reducing human tumor growth will beneﬁt from a better
characterization of the bioenergetic signature of cancer cell lines, in
particular in response to challenging energy conditions, as occurs
during hypoxia and aglycemia.on Ref. Cell-type AICAR mode of action
[36] Leukemia No. 1
[32] HeLa
present HeLa
MRC5
[29] Pancreas No. 2
) [27] Cervical
up) [35] Various
OR (down) [41] Myeloma
present DU145
HEPG2
[46] Breast
[38] Prostate
enesis–mTOR (down) [39] Prostate
own [37] Glioblastoma (EGFR+)
[30] Melanomas No. 3
[58] Neuroblastoma
[34] Breast
[40] Brain tumor
[42] Colon cancer
[43] Colon cancer
[44] Gastric cancer
[45] Astrocytoma
717C. Jose et al. / Biochimica et Biophysica Acta 1807 (2011) 707–718Acknowledgements
We thank the French National Institute for Scientiﬁc and Medical
Research (INSERM), Université Victor Segalen Bordeaux 2, Région
Aquitaine, Ammi, and Cancéropôle Grand Sud-Ouest for ﬁnancial
support. C. Jose was supported by a grant from the FQRNT (Fond
Québecois de la Recherche sur la Nature et les Technologies), E. Hébert
Chatelain by a grant from the Natural Sciences and Engineering
Research Council of Canada, N. Bellance by a grant from INSERM/
Région Aquitaine, and G. Benard by a grant from ANR.
References
[1] A. Isidoro, M. Martinez, P.L. Fernandez, A.D. Ortega, G. Santamaria, M. Chamorro,
J.C. Reed, J.M. Cuezva, Alteration of the bioenergetic phenotype of mitochondria is
a hallmark of breast, gastric, lung and oesophageal cancer, Biochem J 378 (2004)
17–20.
[2] X.L. Zu, M. Guppy, Cancer metabolism: facts, fantasy, and ﬁction, Biochem Biophys
Res Commun 313 (2004) 459–465.
[3] R. Moreno-Sanchez, S. Rodriguez-Enriquez, A. Marin-Hernandez, E. Saavedra,
Energy metabolism in tumor cells, FEBS J 274 (2007) 1393–1418.
[4] F.Weinberg, N.S. Chandel, Mitochondrial metabolism and cancer, Ann NY Acad Sci
1177 (2009) 66–73.
[5] K. Smolkova, L. Plecita-Hlavata, N. Bellance, G. Benard, R. Rossignol, P. Jezek,
Waves of gene regulation suppress and then restore oxidative phosphorylation in
cancer cells, Int J Biochem Cell Biol (2010).
[6] M. Guppy, P. Leedman, X. Zu, V. Russell, Contribution by different fuels and
metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer
cells, Biochem J 364 (2002) 309–315.
[7] S. Rodriguez-Enriquez, L. Carreno-Fuentes, J.C. Gallardo-Perez, E. Saavedra, H.
Quezada, A. Vega, A. Marin-Hernandez, V. Olin-Sandoval, M.E. Torres-Marquez, R.
Moreno-Sanchez, Oxidative phosphorylation is impaired by prolonged hypoxia in
breast and possibly in cervix carcinoma, Int J Biochem Cell Biol (2010).
[8] L. Reitzer, B. Wice, D. Kennel, Evidence that glutamine, not sugar, is the major
energy source for cultured Hela cells, JBC 254 (1979) 2669–2676.
[9] E. Hervouet, A. Cizkova, J. Demont, A. Vojtiskova, P. Pecina, N.L. Franssen-van Hal,
J. Keijer, H. Simonnet, R. Ivanek, S. Kmoch, C. Godinot, J. Houstek, HIF and reactive
oxygen species regulate oxidative phosphorylation in cancer, Carcinogenesis 29
(2008) 1528–1537.
[10] N. Bellance, G. Benard, F. Furt, H. Begueret, K. Smolkova, E. Passerieux, J.P. Delage,
J.M. Baste, P. Moreau, R. Rossignol, Bioenergetics of lung tumors: alteration of
mitochondrial biogenesis and respiratory capacity, Int J Biochem Cell Biol 41
(2009) 2566–2577.
[11] M. Sanchez-Arago, M. Chamorro, J.M. Cuezva, Selection of cancer cells with
repressed mitochondria triggers colon cancer progression, Carcinogenesis 31
(2010) 567–576.
[12] P. Acebo, D. Giner, P. Calvo, A. Blanco-Rivero, A.D. Ortega, P.L. Fernandez, G.
Roncador, E. Fernandez-Malave, M. Chamorro, J.M. Cuezva, Cancer abolishes the
tissue type-speciﬁc differences in the phenotype of energetic metabolism, Transl
Oncol 2 (2009) 138–145.
[13] E. Hervouet, J. Demont, P. Pecina, A. Vojtiskova, J. Houstek, H. Simonnet, C.
Godinot, A new role for the von Hippel–Lindau tumor suppressor protein:
stimulation of mitochondrial oxidative phosphorylation complex biogenesis,
Carcinogenesis 26 (2005) 531–539.
[14] L. Galluzzi, N. Larochette, N. Zamzami, G. Kroemer, Mitochondria as therapeutic
targets for cancer chemotherapy, Oncogene 25 (2006) 4812–4830.
[15] S. Rodriguez-Enriquez, A. Marin-Hernandez, J.C. Gallardo-Perez, L. Carreno-
Fuentes, R. Moreno-Sanchez, Targeting of cancer energy metabolism, Mol Nutr
Food Res 53 (2009) 29–48.
[16] P.L. Pedersen, Tumor mitochondria and the bioenergetics of cancer cells, Prog Exp
Tumor Res 22 (1978) 190–274.
[17] N. Bellance, P. Lestienne, R. Rossignol, Mitochondria: from bioenergetics to the
metabolic regulation of carcinogenesis, Front Biosci 14 (2009) 4015–4034.
[18] S. Rodriguez-Enriquez, J.C. Gallardo-Perez, A. Aviles-Salas, A. Marin-Hernandez, L.
Carreno-Fuentes, V. Maldonado-Lagunas, R. Moreno-Sanchez, Energy metabolism
transition in multi-cellular human tumor spheroids, J Cell Physiol 216 (2008)
189–197.
[19] J.M. Cuezva, G. Chen, A.M. Alonso, A. Isidoro, D.E. Misek, S.M. Hanash, D.G. Beer,
The bioenergetic signature of lung adenocarcinomas is a molecular marker of
cancer diagnosis and prognosis, Carcinogenesis 25 (2004) 1157–1163.
[20] J.M. Cuezva, M. Krajewska, M.L. de Heredia, S. Krajewski, G. Santamaria, H. Kim,
J.M. Zapata, H. Marusawa, M. Chamorro, J.C. Reed, The bioenergetic signature of
cancer: a marker of tumor progression, Cancer Res 62 (2002) 6674–6681.
[21] R. Rossignol, R. Gilkerson, R. Aggeler, K. Yamagata, S.J. Remington, R.A. Capaldi,
Energy substrate modulates mitochondrial structure and oxidative capacity in
cancer cells, Cancer Res 64 (2004) 985–993.
[22] K. Smolkova, N. Bellance, F. Scandurra, E. Genot, E. Gnaiger, L. Plecita-Hlavata, P.
Jezek, R. Rossignol, Mitochondrial bioenergetic adaptations of breast cancer cells
to aglycemia and hypoxia, J Bioenerg Biomembr 42 (2010) 55–67.
[23] L.H. Stockwin, S.X. Yu, S. Borgel, C. Hancock, T.L. Wolfe, L.R. Phillips, M.G.
Hollingshead, D.L. Newton, Sodium dichloroacetate selectively targets cells with
defects in the mitochondrial ETC, Int J Cancer (2010).[24] T.J. Schulz, R. Thierbach, A. Voigt, G. Drewes, B. Mietzner, P. Steinberg, A.F.
Pfeiffer, M. Ristow, Induction of oxidative metabolism by mitochondrial frataxin
inhibits cancer growth: Otto Warburg revisited, J Biol Chem 281 (2006)
977–981.
[25] M. Lagouge, C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N.
Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny, M. Laakso, P. Puigserver, J.
Auwerx, Resveratrol improves mitochondrial function and protects against
metabolic disease by activating SIRT1 and PGC-1alpha, Cell 127 (2006)
1109–1122.
[26] C. Canto, Z. Gerhart-Hines, J.N. Feige, M. Lagouge, L. Noriega, J.C. Milne, P.J. Elliott,
P. Puigserver, J. Auwerx, AMPK regulates energy expenditure by modulating NAD
+ metabolism and SIRT1 activity, Nature 458 (2009) 1056–1060.
[27] W.W. Winder, B.F. Holmes, D.S. Rubink, E.B. Jensen, M. Chen, J.O. Holloszy,
Activation of AMP-activated protein kinase increases mitochondrial enzymes in
skeletal muscle, J Appl Physiol 88 (2000) 2219–2226.
[28] L. Yu, S.J. Yang, AMP-activated protein kinase mediates activity-dependent
regulation of peroxisome proliferator-activated receptor gamma coactivator-
1alpha and nuclear respiratory factor 1 expression in rat visual cortical neurons,
Neuroscience 169 (2010) 23–38.
[29] G.K. McConell, G.P. Ng, M. Phillips, Z. Ruan, S.L. Macaulay, G.D. Wadley, Central
role of nitric oxide synthase in AICAR and caffeine-induced mitochondrial
biogenesis in L6 myocytes, J Appl Physiol 108 (2010) 589–595.
[30] K.S. Persons, V.J. Eddy, S. Chadid, R. Deoliveira, A.K. Saha, R. Ray, Anti-growth effect
of 1, 25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-
amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer
cells, Anticancer Res 30 (2010) 1875–1880.
[31] J. Woodard, L.C. Platanias, AMP-activated kinase (AMPK)-generated signals in
malignant melanoma cell growth and survival, Biochem Biophys Res Commun
398 (2010) 135–139.
[32] S.Y. Yu, D.W. Chan, V.W. Liu, H.Y. Ngan, Inhibition of cervical cancer cell growth
through activation of upstream kinases of AMP-activated protein kinase, Tumour
Biol 30 (2009) 80–85.
[33] T.J. Guan, F.J. Qin, J.H. Du, L. Geng, Y.Y. Zhang, M. Li, AICAR inhibits proliferation
and induced S-phase arrest, and promotes apoptosis in CaSki cells, Acta
Pharmacol Sin 28 (2007) 1984–1990.
[34] J.H. Jung, J.O. Lee, J.H. Kim, S.K. Lee, G.Y. You, S.H. Park, J.M. Park, E.K. Kim, P.G. Suh,
J.K. An, H.S. Kim, Quercetin suppresses HeLa cell viability via AMPK-induced
HSP70 and EGFR down-regulation, J Cell Physiol 223 (2010) 408–414.
[35] C. Garcia-Garcia, C. Fumarola, N. Navaratnam, D. Carling, A. Lopez-Rivas, AMPK-
independent down-regulation of cFLIP and sensitization to TRAIL-induced
apoptosis by AMPK activators, Biochem Pharmacol 79 (2010) 853–863.
[36] R. Rattan, S. Giri, A.K. Singh, I. Singh, 5-Aminoimidazole-4-carboxamide-1-beta-D-
ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-
activated protein kinase, J Biol Chem 280 (2005) 39582–39593.
[37] T.K. Sengupta, G.M. Leclerc, T.T. Hsieh-Kinser, G.J. Leclerc, I. Singh, J.C. Barredo,
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside
(AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for
targeted therapy, Mol Cancer 6 (2007) 46.
[38] D. Guo, I.E. Hildebrandt, R.M. Prins, H. Soto, M.M. Mazzotta, J. Dang, J. Czernin, J.Y.
Shyy, A.D. Watson, M. Phelps, C.G. Radu, T.F. Cloughesy, P.S. Mischel, The AMPK
agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by
inhibiting lipogenesis, Proc Natl Acad Sci USA 106 (2009) 12932–12937.
[39] J. Zhou, W. Huang, R. Tao, S. Ibaragi, F. Lan, Y. Ido, X. Wu, Y.O. Alekseyev, M.E.
Lenburg, G.F. Hu, Z. Luo, Inactivation of AMPK alters gene expression and
promotes growth of prostate cancer cells, Oncogene 28 (2009) 1993–2002.
[40] X. Xiang, A.K. Saha, R. Wen, N.B. Ruderman, Z. Luo, AMP-activated protein kinase
activators can inhibit the growth of prostate cancer cells by multiple mechanisms,
Biochem Biophys Res Commun 321 (2004) 161–167.
[41] P. Mukherjee, T.J. Mulrooney, J. Marsh, D. Blair, T.C. Chiles, T.N. Seyfried,
Differential effects of energy stress on AMPK phosphorylation and apoptosis in
experimental brain tumor and normal brain, Mol Cancer 7 (2008) 37.
[42] P. Baumann, S. Mandl-Weber, B. Emmerich, C. Straka, R. Schmidmaier, Activation
of adenosine monophosphate activated protein kinase inhibits growth of multiple
myeloma cells, Exp Cell Res 313 (2007) 3592–3603.
[43] R.Y. Su, Y. Chao, T.Y. Chen, D.Y. Huang, W.W. Lin, 5-Aminoimidazole-4-
carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in
colon cancer cells through AMP-activated protein kinase signaling, Mol Cancer
Ther 6 (2007) 1562–1571.
[44] Y.M. Kim, J.T. Hwang, D.W. Kwak, Y.K. Lee, O.J. Park, Involvement of AMPK
signaling cascade in capsaicin-induced apoptosis of HT-29 colon cancer cells, Ann
NY Acad Sci 1095 (2007) 496–503.
[45] M. Saitoh, K. Nagai, K. Nakagawa, T. Yamamura, S. Yamamoto, T. Nishizaki,
Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic
pathway relevant to activation of AMP-activated protein kinase, Biochem
Pharmacol 67 (2004) 2005–2011.
[46] K. Sai, D. Yang, H. Yamamoto, H. Fujikawa, S. Yamamoto, T. Nagata, M. Saito, T.
Yamamura, T. Nishizaki, A(1) adenosine receptor signal and AMPK involving
caspase-9/-3 activation are responsible for adenosine-induced RCR-1 astrocytoma
cell death, Neurotoxicology 27 (2006) 458–467.
[47] J.V. Swinnen, A. Beckers, K. Brusselmans, S. Organe, J. Segers, L. Timmermans, F.
Vanderhoydonc, L. Deboel, R. Derua, E. Waelkens, E. De Schrijver, T. Van de Sande,
A. Noel, F. Foufelle, G. Verhoeven, Mimicry of a cellular low energy status blocks
tumor cell anabolism and suppresses the malignant phenotype, Cancer Res 65
(2005) 2441–2448.
[48] C. Rocher, J.W. Taanman, D. Pierron, B. Faustin, G. Benard, R. Rossignol, M. Malgat,
L. Pedespan, T. Letellier, Inﬂuence of mitochondrial DNA level on cellular energy
718 C. Jose et al. / Biochimica et Biophysica Acta 1807 (2011) 707–718metabolism: implications for mitochondrial diseases, J Bioenerg Biomembr 40
(2008) 59–67.
[49] E. Borenfreund, J.A. Puerner, Toxicity determined in vitro by morphological
alterations and neutral red absorption, Toxicol Lett 24 (1985) 119–124.
[50] K. Nouette-Gaulain, N. Bellance, B. Prevost, E. Passerieux, C. Pertuiset, O. Galbes, K.
Smolkova, F. Masson, S. Miraux, J.P. Delage, T. Letellier, R. Rossignol, X. Capdevila,
F. Sztark, Erythropoietin protects against local anesthetic myotoxicity during
continuous regional analgesia, Anesthesiology 110 (2009) 648–659.
[51] G. Benard, N. Bellance, D. James, P. Parrone, H. Fernandez, T. Letellier, R. Rossignol,
Mitochondrial bioenergetics and structural network organization, J Cell Sci 120
(2007) 838–848.
[52] R.J. Youle, M. Karbowski, Mitochondrial ﬁssion in apoptosis, Nat Rev Mol Cell Biol
6 (2005) 657–663.
[53] W.J. Ryves, A.J. Harwood, The interaction of glycogen synthase kinase-3 (GSK-3)
with the cell cycle, Prog Cell Cycle Res 5 (2003) 489–495.[54] M. Monk, C. Holding, Human embryonic genes re-expressed in cancer cells,
Oncogene 20 (2001) 8085–8091.
[55] D. Kukidome, T. Nishikawa, K. Sonoda, K. Imoto, K. Fujisawa, M. Yano, H.
Motoshima, T. Taguchi, T. Matsumura, E. Araki, Activation of AMP-activated
protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen
species production and promotes mitochondrial biogenesis in human umbilical
vein endothelial cells, Diabetes 55 (2006) 120–127.
[56] R.L. Elstrom, D.E. Bauer, M. Buzzai, R. Karnauskas, M.H. Harris, D.R. Plas, H. Zhuang,
R.M. Cinalli, A. Alavi, C.M. Rudin, C.B. Thompson, Akt stimulates aerobic glycolysis
in cancer cells, Cancer Res 64 (2004) 3892–3899.
[57] R. Dixon, J. Gourzis, D. McDermott, J. Fujitaki, P. Dewland, H. Gruber, AICA-
riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating
agent, J Clin Pharmacol 31 (1991) 342–347.
[58] S. Wei, S.K. Kulp, C.S. Chen, Energy restriction as an antitumor target of
thiazolidinediones, J Biol Chem 285 (2010) 9780–9791.
